Liminatus Pharma (LIMN) Competitors

Liminatus Pharma logo
$2.51 -0.30 (-10.68%)
Closing price 11/20/2026 04:00 PM Eastern
Extended Trading
$2.68 +0.17 (+6.77%)
As of 11/20/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

LIMN vs. MRKR, GOVX, KYNB, BCLI, and MCRB

Should you buy Liminatus Pharma stock or one of its competitors? Liminatus Pharma's main competitors and comparable companies include Marker Therapeutics (MRKR), GeoVax Labs (GOVX), Kyntra Bio (KYNB), Brainstorm Cell Therapeutics (BCLI), and Seres Therapeutics (MCRB). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Liminatus Pharma compare to Marker Therapeutics?

Marker Therapeutics (NASDAQ:MRKR) and Liminatus Pharma (NASDAQ:LIMN) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, institutional ownership, valuation, dividends, risk, media sentiment and earnings.

22.4% of Marker Therapeutics shares are held by institutional investors. 5.7% of Marker Therapeutics shares are held by company insiders. Comparatively, 19.4% of Liminatus Pharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Liminatus Pharma's return on equity of 0.00% beat Marker Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Marker TherapeuticsN/A -64.23% -53.79%
Liminatus Pharma N/A N/A -256.58%

Liminatus Pharma has lower revenue, but higher earnings than Marker Therapeutics. Marker Therapeutics is trading at a lower price-to-earnings ratio than Liminatus Pharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Marker Therapeutics$3.55M5.12-$12.16M-$0.39N/A
Liminatus PharmaN/AN/A-$10.21M-$23.50N/A

Marker Therapeutics has a beta of 1.65, meaning that its share price is 65% more volatile than the broader market. Comparatively, Liminatus Pharma has a beta of 4.89, meaning that its share price is 389% more volatile than the broader market.

Marker Therapeutics currently has a consensus price target of $10.00, suggesting a potential upside of 817.43%. Given Marker Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Marker Therapeutics is more favorable than Liminatus Pharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Marker Therapeutics
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.25
Liminatus Pharma
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

In the previous week, Marker Therapeutics had 15 more articles in the media than Liminatus Pharma. MarketBeat recorded 15 mentions for Marker Therapeutics and 0 mentions for Liminatus Pharma. Marker Therapeutics' average media sentiment score of 0.74 beat Liminatus Pharma's score of 0.00 indicating that Marker Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Marker Therapeutics Positive
Liminatus Pharma Neutral

Summary

Marker Therapeutics beats Liminatus Pharma on 9 of the 13 factors compared between the two stocks.

How does Liminatus Pharma compare to GeoVax Labs?

Liminatus Pharma (NASDAQ:LIMN) and GeoVax Labs (NASDAQ:GOVX) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, institutional ownership, valuation, media sentiment, analyst recommendations, risk, profitability and earnings.

6.1% of GeoVax Labs shares are owned by institutional investors. 19.4% of Liminatus Pharma shares are owned by insiders. Comparatively, 0.2% of GeoVax Labs shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Liminatus Pharma's average media sentiment score of 0.00 equaled GeoVax Labs'average media sentiment score.

Company Overall Sentiment
Liminatus Pharma Neutral
GeoVax Labs Neutral

Liminatus Pharma's return on equity of 0.00% beat GeoVax Labs' return on equity.

Company Net Margins Return on Equity Return on Assets
Liminatus PharmaN/A N/A -256.58%
GeoVax Labs N/A -1,010.68%-420.06%

Liminatus Pharma has higher earnings, but lower revenue than GeoVax Labs. Liminatus Pharma is trading at a lower price-to-earnings ratio than GeoVax Labs, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Liminatus PharmaN/AN/A-$10.21M-$23.50N/A
GeoVax Labs$2.49M0.39-$21.47M-$96.65N/A

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Liminatus Pharma
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
GeoVax Labs
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Liminatus Pharma has a beta of 4.89, indicating that its stock price is 389% more volatile than the broader market. Comparatively, GeoVax Labs has a beta of 3.85, indicating that its stock price is 285% more volatile than the broader market.

Summary

Liminatus Pharma beats GeoVax Labs on 6 of the 10 factors compared between the two stocks.

How does Liminatus Pharma compare to Kyntra Bio?

Kyntra Bio (NASDAQ:KYNB) and Liminatus Pharma (NASDAQ:LIMN) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, risk, valuation, dividends and media sentiment.

72.7% of Kyntra Bio shares are held by institutional investors. 4.2% of Kyntra Bio shares are held by insiders. Comparatively, 19.4% of Liminatus Pharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Kyntra Bio presently has a consensus target price of $25.20, suggesting a potential upside of 1,515.38%. Given Kyntra Bio's stronger consensus rating and higher probable upside, equities research analysts clearly believe Kyntra Bio is more favorable than Liminatus Pharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Kyntra Bio
1 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.57
Liminatus Pharma
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Kyntra Bio has higher revenue and earnings than Liminatus Pharma. Kyntra Bio is trading at a lower price-to-earnings ratio than Liminatus Pharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kyntra Bio$6.44M0.98$183.45M-$4.27N/A
Liminatus PharmaN/AN/A-$10.21M-$23.50N/A

Kyntra Bio has a net margin of 2,199.13% compared to Liminatus Pharma's net margin of 0.00%.

Company Net Margins Return on Equity Return on Assets
Kyntra Bio2,199.13% N/A -66.00%
Liminatus Pharma N/A N/A -256.58%

Kyntra Bio has a beta of 1.08, suggesting that its stock price is 8% more volatile than the broader market. Comparatively, Liminatus Pharma has a beta of 4.89, suggesting that its stock price is 389% more volatile than the broader market.

In the previous week, Kyntra Bio had 10 more articles in the media than Liminatus Pharma. MarketBeat recorded 10 mentions for Kyntra Bio and 0 mentions for Liminatus Pharma. Kyntra Bio's average media sentiment score of 0.23 beat Liminatus Pharma's score of 0.00 indicating that Kyntra Bio is being referred to more favorably in the media.

Company Overall Sentiment
Kyntra Bio Neutral
Liminatus Pharma Neutral

Summary

Kyntra Bio beats Liminatus Pharma on 11 of the 13 factors compared between the two stocks.

How does Liminatus Pharma compare to Brainstorm Cell Therapeutics?

Liminatus Pharma (NASDAQ:LIMN) and Brainstorm Cell Therapeutics (NASDAQ:BCLI) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, valuation, risk, media sentiment and profitability.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Liminatus Pharma
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Brainstorm Cell Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

In the previous week, Brainstorm Cell Therapeutics had 4 more articles in the media than Liminatus Pharma. MarketBeat recorded 4 mentions for Brainstorm Cell Therapeutics and 0 mentions for Liminatus Pharma. Brainstorm Cell Therapeutics' average media sentiment score of 0.92 beat Liminatus Pharma's score of 0.00 indicating that Brainstorm Cell Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Liminatus Pharma Neutral
Brainstorm Cell Therapeutics Positive

Liminatus Pharma has a beta of 4.89, indicating that its share price is 389% more volatile than the broader market. Comparatively, Brainstorm Cell Therapeutics has a beta of 0.35, indicating that its share price is 65% less volatile than the broader market.

14.3% of Brainstorm Cell Therapeutics shares are owned by institutional investors. 19.4% of Liminatus Pharma shares are owned by company insiders. Comparatively, 11.2% of Brainstorm Cell Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Brainstorm Cell Therapeutics is trading at a lower price-to-earnings ratio than Liminatus Pharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Liminatus PharmaN/AN/A-$10.21M-$23.50N/A
Brainstorm Cell TherapeuticsN/AN/A-$11.62M-$1.42N/A

Company Net Margins Return on Equity Return on Assets
Liminatus PharmaN/A N/A -256.58%
Brainstorm Cell Therapeutics N/A N/A -519.50%

Summary

Liminatus Pharma beats Brainstorm Cell Therapeutics on 5 of the 9 factors compared between the two stocks.

How does Liminatus Pharma compare to Seres Therapeutics?

Liminatus Pharma (NASDAQ:LIMN) and Seres Therapeutics (NASDAQ:MCRB) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, dividends, profitability, valuation, institutional ownership, risk, earnings and analyst recommendations.

Seres Therapeutics has higher revenue and earnings than Liminatus Pharma. Seres Therapeutics is trading at a lower price-to-earnings ratio than Liminatus Pharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Liminatus PharmaN/AN/A-$10.21M-$23.50N/A
Seres Therapeutics$790K16.11$5.70M-$5.00N/A

In the previous week, Seres Therapeutics had 4 more articles in the media than Liminatus Pharma. MarketBeat recorded 4 mentions for Seres Therapeutics and 0 mentions for Liminatus Pharma. Liminatus Pharma's average media sentiment score of 0.00 beat Seres Therapeutics' score of -1.00 indicating that Liminatus Pharma is being referred to more favorably in the media.

Company Overall Sentiment
Liminatus Pharma Neutral
Seres Therapeutics Negative

59.3% of Seres Therapeutics shares are held by institutional investors. 19.4% of Liminatus Pharma shares are held by company insiders. Comparatively, 5.2% of Seres Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Seres Therapeutics has a consensus target price of $17.00, suggesting a potential upside of 1,261.09%. Given Seres Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Seres Therapeutics is more favorable than Liminatus Pharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Liminatus Pharma
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Seres Therapeutics
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.25

Liminatus Pharma has a net margin of 0.00% compared to Seres Therapeutics' net margin of -2,209.55%. Liminatus Pharma's return on equity of 0.00% beat Seres Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Liminatus PharmaN/A N/A -256.58%
Seres Therapeutics -2,209.55%-194.42%-58.15%

Liminatus Pharma has a beta of 4.89, suggesting that its stock price is 389% more volatile than the broader market. Comparatively, Seres Therapeutics has a beta of 0.44, suggesting that its stock price is 56% less volatile than the broader market.

Summary

Seres Therapeutics beats Liminatus Pharma on 9 of the 14 factors compared between the two stocks.

Get Liminatus Pharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for LIMN and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LIMN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

LIMN vs. The Competition

MetricLiminatus PharmaBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$3.37M$3.93B$7.43B$10.86B
Dividend YieldN/A3.79%2.51%4.74%
P/E RatioN/A24.5831.2925.82
Price / SalesN/A15.328.115.44
Price / CashN/A21.9220.2520.77
Price / Book-0.144.124.343.51
Net Income-$10.21M-$24.08M$3.51B$394.12M
1 Month Performance-19.55%-13.58%-10.59%-12.04%
1 Year Performance-93.02%-7.97%-4.80%-11.42%

Liminatus Pharma Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
LIMN
Liminatus Pharma
N/A$2.51
-10.7%
N/A-95.2%$3.37MN/AN/A1
MRKR
Marker Therapeutics
2.3047 of 5 stars
$0.92
-3.3%
$10.00
+988.1%
+9.6%$15.32M$3.55MN/A5
GOVX
GeoVax Labs
1.0972 of 5 stars
$2.04
-5.8%
$3,600.00
+176,804.2%
-99.2%$14.81M$2.49MN/A19
KYNB
Kyntra Bio
2.913 of 5 stars
$3.63
-1.5%
$36.80
+915.2%
N/A$14.68M$4.62M0.0834
BCLI
Brainstorm Cell Therapeutics
N/A$0.97
-2.0%
N/A+19.6%$14.36MN/AN/A19

Related Companies and Tools


This page (NASDAQ:LIMN) was last updated on 11/21/2026 by MarketBeat.com Staff.
From Our Partners